CRIS

Curis, Inc. NASDAQ

Healthcare ·Biotechnology ·US · curis.com

$0.58

Mkt Cap $7.6M

52w Low $0.49 3.4% of range 52w High $3.13

50d MA $0.76 200d MA $1.23

P/E (TTM) -1.0x

EV/EBITDA -3.9x

P/B 14.3x

Debt/Equity 0.3x

ROE -138.8%

P/FCF -4.8x

RSI (14) —

ATR (14) —

Beta 3.14

50d MA $0.76

200d MA $1.23

Avg Volume 416.1K

About

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-89…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 19, 2026	AMC	-0.44	-0.50	-14.7%	0.76	+0.7%	+1.9%	-2.3%	-5.5%	-7.5%	-23.4%	-18.5%	—
Nov 6, 2025	AMC	-0.62	-0.49	+21.0%	1.46	-7.5%	-10.3%	-10.3%	-14.4%	-15.8%	-22.6%	-7.5%	—
Aug 5, 2025	AMC	-1.99	-0.68	+65.8%	1.67	+0.6%	+0.0%	+3.0%	+2.4%	-2.4%	-1.2%	+2.4%	—
May 6, 2025	AMC	-1.14	-1.25	-9.6%	2.19	-0.9%	-5.9%	-4.1%	-13.7%	-10.5%	-3.2%	+9.1%	—
Mar 31, 2025	AMC	-1.36	-1.25	+8.1%	2.10	+1.0%	-30.5%	-29.5%	-36.7%	-41.4%	-44.8%	+0.5%	—
Nov 14, 2024	AMC	-1.88	-1.70	+9.6%	3.98	+0.0%	-0.8%	-4.5%	-4.8%	-7.0%	+3.0%	-12.6%	—
Aug 1, 2024	AMC	-1.70	-2.03	-19.4%	4.94	+1.2%	+1.2%	-2.6%	-2.8%	-10.7%	-8.9%	+6.5%	—
May 7, 2024	AMC	-1.94	-2.05	-5.7%	16.20	+3.7%	+0.9%	+1.9%	-3.0%	-3.3%	-3.1%	-40.3%	—
Feb 8, 2024	AMC	-1.91	-2.03	-6.3%	10.65	-3.0%	-2.3%	+0.7%	-4.8%	-3.4%	-4.0%	-2.8%	—
Dec 21, 2023	AMC	—	-2.58	—	12.69	-1.3%	+8.6%	+10.7%	+11.1%	+9.5%	+0.5%	-10.6%	—
Nov 2, 2023	AMC	-2.32	-2.13	+8.2%	4.51	+1.1%	+1.3%	+18.4%	+20.4%	+37.7%	+39.5%	+131.5%	—
Aug 3, 2023	AMC	-2.40	-2.40	+0.0%	15.42	-0.5%	-8.8%	-20.6%	-16.3%	-14.9%	-15.9%	-27.8%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.76	$0.76	+0.7%	+1.9%	-2.3%	-5.5%	-7.5%	-23.4%
Mar 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.32	$2.30	-0.9%	-9.5%	-37.1%	-36.2%	-42.7%	-47.0%
Dec 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.14	$4.08	-1.4%	-4.3%	-8.0%	-10.1%	-13.8%	-15.9%
Nov 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.98	$3.98	+0.0%	-0.8%	-4.5%	-4.8%	-7.0%	+3.0%
Nov 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.28	$4.38	+2.3%	-2.3%	+1.2%	+3.3%	-1.9%	+1.6%
Aug 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.48	$5.48	+0.0%	-9.9%	-8.8%	-12.2%	-12.4%	-19.5%
May 15	Truist	Maintains	Buy → Buy	—	$15.69	$15.34	-2.2%	-17.1%	-19.7%	-24.8%	-33.0%	-31.2%
May 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.69	$15.34	-2.2%	-17.1%	-19.7%	-24.8%	-33.0%	-31.2%
May 8	HC Wainwright& Co.	Maintains	Buy → Buy	—	$16.20	$16.80	+3.7%	+0.9%	+1.9%	-3.0%	-3.3%	-3.1%
May 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.20	$16.80	+3.7%	+0.9%	+1.9%	-3.0%	-3.3%	-3.1%
Feb 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.65	$10.33	-3.0%	-2.3%	+0.7%	-4.8%	-3.4%	-4.0%
Sep 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.60	$6.00	-21.1%	-13.3%	-31.6%	-29.2%	-34.1%	-34.7%
Sep 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.61	$8.80	+2.2%	-11.7%	-23.5%	-39.6%	-37.5%	-41.8%
Sep 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.01	$8.91	-1.1%	-4.9%	-6.1%	-4.4%	-15.6%	-26.9%
Sep 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	—	—	—	—	—	—	—	—
Sep 7	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$10.62	$10.52	-0.9%	-0.6%	-0.6%	-3.9%	-3.6%	-4.1%
Sep 6	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$11.13	$11.76	+5.7%	-4.6%	-5.1%	-5.1%	-8.3%	-8.0%
Aug 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.42	$15.34	-0.5%	-8.8%	-20.6%	-16.3%	-14.9%	-15.9%
Aug 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.89	$15.80	-0.6%	-3.0%	-11.5%	-22.9%	-18.8%	-17.4%
Jul 11	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$17.40	$17.24	-0.9%	-3.4%	+0.0%	-4.2%	-7.8%	-9.2%
Jul 10	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$16.20	$16.70	+3.1%	+7.4%	+3.8%	+7.4%	+2.9%	-0.9%
Jul 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.88	$17.10	+1.3%	-4.0%	+3.1%	-0.4%	+3.1%	-1.2%
Jul 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.41	$15.00	-8.6%	+2.9%	-1.3%	+6.0%	+2.4%	+6.0%
May 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$16.76	$16.00	-4.5%	-3.9%	-4.6%	-0.8%	+3.5%	+8.6%
Nov 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.44	$16.00	+10.8%	+13.6%	+20.5%	+24.2%	+26.2%	+23.9%
Nov 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.60	$15.40	-1.3%	-7.4%	+5.1%	+11.5%	+15.0%	+16.9%
Apr 5	Raymond James	Downgrade	Outperform → Market Perform	—	$32.40	$32.80	+1.2%	-7.4%	-9.3%	-9.9%	-11.1%	-18.5%
Apr 5	B. Riley Securities	Maintains	Buy → Buy	—	$32.40	$32.80	+1.2%	-7.4%	-9.3%	-9.9%	-11.1%	-18.5%
Apr 4	Raymond James	Downgrade	Outperform → Market Perform	—	$48.60	$32.60	-32.9%	-33.3%	-38.3%	-39.5%	-39.9%	-40.7%
Apr 4	B. Riley Securities	Maintains	Buy → Buy	—	$48.60	$32.60	-32.9%	-33.3%	-38.3%	-39.5%	-39.9%	-40.7%
Oct 13	Raymond James	Maintains	Outperform → Outperform	—	$150.80	$156.80	+4.0%	+0.4%	+0.7%	-3.8%	-1.5%	+0.8%
Mar 25	B. Riley Securities	Maintains	Buy → Buy	—	$206.20	$206.00	-0.1%	+14.6%	+10.7%	+9.2%	+10.6%	+9.8%
Mar 25	B. Riley FBR	Maintains	Buy → Buy	—	$206.20	$206.00	-0.1%	+14.6%	+10.7%	+9.2%	+10.6%	+9.8%
Jan 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$235.80	$242.00	+2.6%	+8.6%	+4.7%	-2.0%	-5.9%	-7.0%
Jan 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$210.80	$211.20	+0.2%	+11.9%	+21.4%	+17.1%	+9.6%	+5.2%
Dec 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$28.80	$109.40	+279.9%	+354.9%	+434.0%	+460.8%	+447.9%	+469.4%
Dec 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$37.60	$38.20	+1.6%	-23.4%	+248.4%	+309.0%	+329.5%	+319.7%
Nov 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$27.00	$28.00	+3.7%	+1.5%	+1.5%	+6.7%	+7.4%	+13.3%
Jul 17	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$23.60	$24.60	+4.2%	+5.1%	+8.1%	+17.8%	+16.1%	+10.2%
May 7	Baird	Maintains	Outperform → Outperform	—	$50.19	$51.65	+2.9%	+1.0%	-2.4%	+1.2%	+3.3%	+4.3%
May 6	Baird	Maintains	Outperform → Outperform	—	—	—	—	—	—	—	—	—
Oct 24	Guggenheim	Maintains	Buy → Buy	—	$157.00	$170.00	+8.3%	+5.1%	+4.5%	+1.3%	-0.6%	+1.9%
Mar 1	SunTrust Robinson Humphrey	Maintains	Buy → Buy	—	$137.00	$141.00	+2.9%	+9.5%	+21.2%	+30.7%	+28.5%	+29.2%
Aug 11	FBR Capital	Maintains	Outperform → Outperform	—	$254.00	$258.00	+1.6%	+2.4%	+2.8%	+13.4%	+10.6%	+15.0%
Jun 1	Baird	Maintains	Outperform → Outperform	—	$337.00	$339.00	+0.6%	-1.8%	+3.9%	+3.9%	+1.2%	+4.5%
May 31	Baird	Maintains	Outperform → Outperform	—	—	—	—	—	—	—	—	—
May 9	Oppenheimer	Maintains	Outperform → Outperform	—	$194.00	$191.00	-1.5%	+3.6%	+6.2%	+3.1%	+2.1%	-1.5%
May 8	Oppenheimer	Maintains	Outperform → Outperform	—	$201.00	$202.00	+0.5%	-3.5%	+0.0%	+2.5%	-0.5%	-1.5%
Dec 6	Wedbush	Maintains	Outperform → Outperform	—	$338.00	$362.00	+7.1%	+1.5%	-17.5%	-18.0%	-27.2%	-25.1%
Dec 5	Wedbush	Maintains	Outperform → Outperform	—	$332.00	$332.00	+0.0%	+1.8%	+3.3%	-16.0%	-16.6%	-25.9%

Recent Filings

8-K

Curis, Inc. -- 8-K Filing

Curis Inc. faces delisting from Nasdaq Capital Market on May 6, 2026, due to failing the minimum bid price rule, though the company plans to appeal the determination.

May 1

8-K

Unknown — 8-K Filing

Curis's emavusertib showed clinical progress in primary CNS lymphoma, potentially expanding its market opportunity beyond initial indications and validating the IRAK4/FLT3 inhibitor approach.

Mar 19

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

Curis Inc. approved a substantial equity incentive pool (25M shares) for executive compensation, increasing dilution risk for existing shareholders and signaling significant executive retention/motivation efforts ahead.

Mar 17

8-K

Curis Inc -- 8-K Filing

Curis Inc faces potential delisting risks from Nasdaq, creating uncertainty about the company's continued public trading status and investor liquidity.

Feb 9

Data updated apr 25, 2026 3:14am · Source: massive.com